Royal college

Dr. Verna Yiu appointed to EPCOR Board of Directors

Retrieved on: 
Wednesday, November 1, 2023

EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.

Key Points: 
  • EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.
  • "Dr. Yiu is highly recognized for her dedication and leadership in the fields of medicine and academia, as well as for her commitment to advancing the health and outlook of the patients in her care and the communities she serves," said Janice G. Rennie, EPCOR Board Chair.
  • We are fortunate and pleased to welcome her to our Board."
  • In addition to previous faculty leadership roles at the University of Alberta, Dr. Yiu served as the Executive Vice-President and Chief Medical Officer (2012-2016) and then as the President and CEO (2016-2022) of Alberta Health Services.

Spectral AI names Prof. Paul Chadwick, Former CEO of the Royal College of Podiatry UK, as Senior Executive for UK and EMEA

Retrieved on: 
Tuesday, October 24, 2023

“Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team.

Key Points: 
  • “Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team.
  • The Royal College of Podiatry is an extremely prestigious and important organization where Paul most recently served for over six years in senior executive capacities, including CEO.
  • In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization.
  • with a focus on foot ulceration from Manchester Metropolitan University and holds an undergraduate degree in Science Honors from the University of Brighton.

LAST CHANCE: ONLY SIX DAYS LEFT TO GET YOUR HANDS ON AN ICONIC PIECE OF DISNEY STORYTELLING IN SUPPORT OF MAKE-A-WISH®

Retrieved on: 
Tuesday, October 24, 2023

BURBANK, Calif., Oct. 24, 2023 /PRNewswire/ -- For the next six days, fans around the world can bid on 100 unique items, artworks and experiences donated by some of the world's most notable creators and next generation visionaries to celebrate 100 years of storytelling. Each item is inspired by the creator's personal connection to stories and characters across Disney, Pixar, Marvel, Star Wars and 20th Century Studios. The auction is currently running across 18 countries until Monday October 30, 2023, benefiting Make-A-Wish.  Virgil Abloh Securities kicked off the campaign in July by revealing a 6-foot structural sculpture of Sorcerer's Apprentice Mickey at the Royal College of Art in London. The life-size piece titled 'Structural Sorcerer — a Sorcerer's Apprentice Mickey Sculpture' was commissioned by Disney and designed by ALASKA ALASKA. Since then, Create 100 has continued to unveil a dazzling slate of items and experiences created by some of the most prolific creators of today.

Key Points: 
  • Each item is inspired by the creator's personal connection to stories and characters across Disney, Pixar, Marvel, Star Wars and 20th Century Studios.
  • The auction is currently running across 18 countries until Monday October 30, 2023, benefiting Make-A-Wish.
  • The life-size piece titled 'Structural Sorcerer — a Sorcerer's Apprentice Mickey Sculpture' was commissioned by Disney and designed by ALASKA ALASKA.
  • To explore the auction lineup and place a bid, visit https://us.disneycreate100.givergy.com/us/ and to access high-res assets, visit here.

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

Retrieved on: 
Tuesday, October 3, 2023

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Shephard (Shep) Mpofu, MD, MRCP, FRCP as Senior Vice President of Development. Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company’s Senior Leadership Team.

Key Points: 
  • Dr. Mpofu will be responsible for leading clinical development as well as translational sciences and will also join the company’s Senior Leadership Team.
  • “Shep is an internationally recognized immunologist and rheumatologist as well as an esteemed colleague.
  • Dr Mpofu is a United Kingdom General Medical Council Board-certified rheumatologist, who previously practiced at several institutions in the United Kingdom (UK) prior to joining industry.
  • “I am very excited to join the rapidly growing team at ACELYRIN and strongly believe in the company’s potential to advance transformative medicines for patients,” said Dr. Mpofu.

The Way of the Ancestors and how it can help us hear The Voice

Retrieved on: 
Tuesday, October 3, 2023

The book opens a window into the private Aboriginal world of law, justice and politics.

Key Points: 
  • The book opens a window into the private Aboriginal world of law, justice and politics.
  • But the thrust of The Way of the Ancestors goes deeper into the law governing human relationships, authority, justice, reconciliation, and the settling of grievances (Makarrata).
  • Already published are those on Songlines, Design, Country, Astronomy and Plants, with an edition on Innovation to be released shortly.
  • Indeed, for the first time the outside world is permitted to glimpse the deep concepts, practices, and emotions of a way of living that sustained 2000 generations.

Building ‘moral muscle’

    • The colonisers’ common law, while containing provisions respecting individual rights, was largely intended to protect property and good order.
    • The constitution they constructed for Federation, explicitly excluded First Peoples, along with Chinese and other non-Europeans, from citizenship.
    • Indigenous law’s purpose is not to protect the wealth, power, and property of the leadership class.
    • The capital of Indigenous society is intellectual and moral, not material, and the law is about proper behaviour towards other people and the natural world.
    • Indigenous Law has evolved to ensure the wellbeing of the society by building the inner wellbeing of individuals and collective wellbeing.
    • The Yolungu see this as the building of “moral muscle”.

Managing emotions

    • Central to traditional life is learning to manage emotions, feelings that can be both productive and hideously destructive.
    • One strategy is the use of Pitjantjatjara/English fridge magnets containing the words for around 50 emotions in both languages.
    • Senior women had observed that young people, especially young males, could not express their emotions in either their own language or in English.

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Monday, October 2, 2023

“Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.

Key Points: 
  • “Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • “We have built our leadership team with experienced industry leaders who have proven track records of success with multiple drug approvals.
  • Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.
  • Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies.

Syniverse CEO Andrew Davies Joins CTIA Board of Directors

Retrieved on: 
Monday, October 2, 2023

Syniverse , "the world's most connected company,"® announces that CEO Andrew Davies has been appointed to CTIA’s Board of Directors.

Key Points: 
  • Syniverse , "the world's most connected company,"® announces that CEO Andrew Davies has been appointed to CTIA’s Board of Directors.
  • Davies, Syniverse's CEO since March 2021, brings more than two decades of telecom leadership to the board.
  • "CTIA and Syniverse have long been partners in shaping the mobile ecosystem, and now we're entering a new era marked by the rollout of 5G networks across the U.S.," said Davies.
  • He currently serves as a Board Member on the Florida Chamber of Commerce and is a Wall Street Journal CEO Council member.

CMR Surgical surpasses 15,000 surgical procedures on Versius® globally as it raises $165 million to support continued growth

Retrieved on: 
Wednesday, September 20, 2023

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.

Key Points: 
  • The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.
  • CMR Surgical (CMR or ‘the Company’) – the global surgical robotics business – has today announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.
  • The surgical cases span more than 130 complex and benign procedure types including colectomies, hernia repairs, hysterectomies, sacrocolpopexies, and lobectomies across seven surgical specialties.
  • CMR’s vision is to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place globally.

CMR Surgical surpasses 15,000 surgical procedures on Versius® globally as it raises $165 million to support continued growth

Retrieved on: 
Wednesday, September 20, 2023

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.

Key Points: 
  • The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.
  • CMR Surgical (CMR or ‘the Company’) – the global surgical robotics business – has today announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.
  • The surgical cases span more than 130 complex and benign procedure types including colectomies, hernia repairs, hysterectomies, sacrocolpopexies, and lobectomies across seven surgical specialties.
  • CMR’s vision is to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place globally.